Introduction {#s1}
============

A contemporary view of tumorigenesis is that transformation results as a multi-step process involving genetic, epigenetic, cellular and tissue-associated changes [@pone.0070398-Xie1], [@pone.0070398-Dumont1], [@pone.0070398-Hruban1]. These effect alterations in several regulatory and functional networks within the cell that lead to a progressive acquisition of capabilities of self-sufficiency in growth signals, insensitivity to anti-growth signals, unlimited replicative potential, evasion of apoptotic signals, tissue invasion and metastasis, and sustained angiogenesis [@pone.0070398-Hanahan1]. More lately, energy metabolism reprogramming and evading immune destruction have received recognition as additional hallmarks of transformation [@pone.0070398-Hanahan2].

Epithelial Ovarian Cancer (EOC) is recognized as the fifth most common cancer and the highest cause of cancer-related deaths among woman [@pone.0070398-AmCan1], [@pone.0070398-Jemal1]. A limitation in EOC studies is the lack of identification of pre-neoplastic lesions that lead to rapid and aggressive metastasis, at which stage the disease is most frequently diagnosed. This is further made more complex from recent findings that suggest high-grade EOC to originate in the fallopian tube epithelia, in contrast to the classical opinion of the ovarian surface epithelia being the cell of origin [@pone.0070398-Levanon1], [@pone.0070398-Bell1]. Though contemporary proteome analyses provide a dynamic and efficient source of identification of tumor suppressors, oncogenes, cancer diagnostics and therapeutics [@pone.0070398-Elenbaas1], [@pone.0070398-Kislinger1], [@pone.0070398-Hanash1], [@pone.0070398-Kulasingam1], an extended understanding of the multi-step transformation events in EOC vis-a-vis altered molecular expressions among transformed and pre-transformed cells remains to be resolved.

The present study is based on proteomic profiling of an *in vitro* model of serous ovarian adenocarcinoma (SeOvCa) established earlier in our lab [@pone.0070398-Bapat1]. Briefly, we had established several single-cell clone derived cultures from the malignant ascites of a Grade IV serous ovarian adenocarcinoma patient. Nineteen of these underwent spontaneous immortalization and were established as continuous lines. The A4 clone was one of these clones. In its initial passages, it was seen to be slow-cycling and non-tumorigenic; however, around passage 20--25 it transformed into an aggressively tumorigenic clone with metastatic capabilities. This data suggests that early A4 cells, although lacking tumorigenecity had already acquired some of the features of transformation. Hence we referred to these as being pre-transformed (A4-P), while the transformed cells derived from A4-P cells were termed as A4-T. This provided us a suitable progression model of two functionally discrete cell groups derived from a single clone in the tumor. Proteome profiles of this A4 progression model resolved through 2-Dimension Gel Electrophoresis (2DE) followed by MS (MALDI-TOF/TOF) led to the derivation of specific protein groups based on their exclusive and differential expression patterns.

Characterization of the functional networks defined by such proteins provided a clear insight into altered cellular functionality and major pathways involved in ovarian cell transformation. Of these, RXR-γ modulated cellular differentiation and apoptosis were exclusive to the pre-transformed cells. Modulation of retinol metabolism has been suggested in association with EOC progression [@pone.0070398-Kuppumbatti1], [@pone.0070398-Roberts1] in which decreased levels of CRBP1 (cellular retinol-binding protein-1) are considered a crucial step in progression of the transformation process [@pone.0070398-Cvetkovic1]. However, the precise relevance of RXR-γ signaling remains largely uncharacterized. We resolved its functional role in the transformed cells of our progression model through induction of expression by treatment with selective retinoids including 9*Cis*-Retinoic acid (CRA), Adapalane (ADA) and 4-\[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl\] benzoic acid (TTNPB). Such modulation of cellular differentiation and apoptosis by RXR-γ in SeOvCa further extends our current understanding of cellular transformation.

Results {#s2}
=======

Comparative protein expression analysis of A4-P and A4-T epithelial ovarian cancer progression model {#s2a}
----------------------------------------------------------------------------------------------------

The functionally different A4-P and A4-T epithelial ovarian cancer cells exhibit a distinct phenotype, with the former being spindle-shaped while the latter appear epithelial-like in morphology ([Fig. 1A](#pone-0070398-g001){ref-type="fig"}). 2-DE gels were prepared using proteome samples of A4-P and A4-T cells. Two technical sets of 2-DE analytical gels were prepared from each phenotype in each experiment, which was carried out in triplicate (total 6 replicates) and silver-stained. Scanned images were processed using PDQuest and proteins with differential expression were annotated. An average, 400--500 differential protein spots were thus demarcated. Annotation of spots led to the derivation of protein sets based on their expression patterns in each cell type. Towards identification of differential protein expression, selected protein spots were digested and mass spectra was generated in MS/MS analyses. GPS Explorer software (v.3.6) was used to submit the combined MS and MS/MS data from MALDI-TOF/TOF to Mascot against SwissProt database. For all proteins thus analysed, reasonable sequence coverage, low index of mass errors and high confidence interval (CI ≥95%) were obtained.

![Expression profiling of the proteome of serous ovarian adenocarcinoma progression model.\
A. Morphological differences between A4 pre-transformed (A4-P) and A4 transformed (A4-T) cells (Bar 100μ). B, Analytical pipeline; Lower Panel-Representative gel images showing exclusively expressed proteins in A4-P cells (left -- EEx) and A4-T cells (right -- LEx). C, Venn diagram showing proteins categorized under all 4 sub-groups. D.i-ii, Pie diagram showing molecular functionality and pathways associated with identified A4-P and A4-T proteins respectively. E, Quantitative protein expression of Vimentin, Cytokeratin-8 and Cytokeratin-18; data shown are representative of 3 separate experiments depicted as mean ± SEM \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.00.](pone.0070398.g001){#pone-0070398-g001}

Derivation of the protein groups based on expression pattern {#s2b}
------------------------------------------------------------

MS/MS based protein identification led to derivation of two groups of differentially expressed proteins ([Fig. 1B](#pone-0070398-g001){ref-type="fig"}). *Group I* comprised of proteins that were expressed qualitatively (exclusively) in either A4-P or A4-T (termed as EEx and LEx proteins respectively), while *Group II* includes proteins expressed at quantitatively different levels (minimum two-fold differential expression between the two cell types). Both groups were further divided into two sub-groups based on their expressions in respective cell types. Annotation of qualitative and quantitative expressions was performed within each replicative set of A4-P and A4-T cells. A total of 10 and 34 *Group I* proteins and, 31 and 48 *Group II* proteins were identified as being expressed in A4-P and A4-T cells respectively ([Fig. 1C](#pone-0070398-g001){ref-type="fig"}; [Table S1](#pone.0070398.s002){ref-type="supplementary-material"}). [Tables 1](#pone-0070398-t001){ref-type="table"} & [2](#pone-0070398-t002){ref-type="table"} lists the identified *Group I* and *Group II* proteins with specific spot numbers, molecular and functional description along with the details of match peptides, protein score, sequence coverage (%) and relative expression fold-change.

10.1371/journal.pone.0070398.t001

###### Details of proteins identified through 2DE followed by MALDI-TOF (MS/MS) analysis in Group I.

![](pone.0070398.t001){#pone-0070398-t001-1}

  Sub-group I. Proteins qualitatively expressed in A4-P cells.                                                                                                                                                                                                    
  -------------------------------------------------------------- -------- ------------------------------------------------------- --------------------------------------------------------------- ------------- ------- ------- ------------ ---- ----- ---- ---- --------
  **1**                                                           P07339                   Cathapsin D precursor                                      Cell death/proteolysis                       CATD_HUMAN    CTSD    1509    44524/6.10   11   244   37   43     2D
  **2**                                                           P29992   Guanine nucleotide binding protein G(y) alpha subunit                Protein amino adic ADP-ribosylation                GNA11_HUMAN   GNA11   2767    42097/5.11   7    49    20   49     2D
  **3**                                                           Q9P2J3                   Kelch like protein -9                                      Ubl conjugation pathway                      KLHL9_HUMAN   KLHL9   55958   69383/5.92   13   39    23   73     2D
  **4**                                                           Q8NEV4                         Myosin 3A                                 Autophosphorylation and response to stimulus            MYO3A_HUMAN   MYO3A   53904   185966/9.0   21   41    14   64     2D
  **5**                                                           Q8WXW3           Progestrone induced blocking factor-1                               Progestrone mediator                        PIB1_HUMAN    PIBF1   10464   89719/5.77   13   43    20   30     2D
  **6**                                                           P48443             RXR gamma retinoic acid receptor              Transcriptional regulation, differentiation and proliferation   LMO7_HUMAN    RXRG    6258    50838/7.55   11   39    19   69   2D: IB
  **7**                                                           Q15293                Reticulocalbin 1 precursor                                  endoplasmic reticulum lumen                    RCN1_HUMAN    RCN1    5954    38866/4.86   8    68    23   22     2D
  **8**                                                           P08758                        Annexin A5                                       anti-apoptosis/blood coagulation                  ANXA5_HUMAN   ANXA5    308    35783/4.94   18   243   66   23     2D
  **9**                                                           Q13162                      Peroxiredoxin 4                             I-kappaB phosphorylation/cell redox homeostasis          PRDX4_HUMAN   PRDX4   10549   30521/5.86   11   208   49   11     2D
  **10**                                                          P09493                   Tropomyosin 1 α chain                                Actin binding and cellular dynamics                TMP1_HUMAN    TPM1    7168    32689/4.69   11   146   21   10     2D

  Sub-group II. Proteins qualitatively expressed in A4-T cells.                                                                                                                                                                                                        
  --------------------------------------------------------------- -------- ------------------------------------------------------------------ ----------------------------------------------------- ------------- --------- ------- ------------- ---- ----- ---- ---- --------
  **1**                                                            P13010                    ATP-dependent DNA helicase II,                           DNA Repair and telomerase maintenance          KU86_HUMAN     XRCC5    7520    82521/5.55    17   194   24   20   2D: IB
  **2**                                                            Q9Y696               Chloride intracellular channel protein 4                   Cell diffrentiation and chloride transport        CLIC4_HUMAN    CLIC4    25932   28754/5.45    9    123   44   28     2D
  **3**                                                            Q05823             2-5A-dependent ribonuclease (Ribonuclease L)                 mRNA processing and protein phosphorylation       RN5A_HUMAN    RNASEL    6041    83481/6.20    13   33    20   54     2D
  **4**                                                            P49368                  T-complex protein 1, gamma subunit                                    Protein folding                     TCPG_HUMAN     CCT3     7203    60364/6.10    12   56    22   24     2D
  **5**                                                            P68104                             EF-1-alpha-1                                           Translation elongatrion                 EF1A1_HUMAN   EEF1A1    1915    50109/9.10    9    80    22   15     2D
  **6**                                                            P09104                            Gamma enolase                                                 Glycolysis                        ENOG_HUMAN     ENO2     2026    47108/4.91    8    98    27   22     2D
  **7**                                                            O00629                       Importin alpha-4 subunit                                        Protein trasport                     IMA4_HUMAN     KPNA4    3804    57851/4.80    9    142   22   21     2D
  **8**                                                            P06748                         Nucleophosmin (NPM)                                        Anti-apoptotic function                  NPM_HUMAN     NPM1     4869    32555/4.64    6    149   28   50   2D: IB
  **9**                                                            P30101               Protein disulfide-isomerase A3 precursor                    Redox homeostasis and signal transduction        PDIA3_HUMAN    PDIA3    2923    56747/5.98    15   146   30   34     2D
  **10**                                                           P14618                           Pyruvate kinase                                    Gycoloysis & programmed cell death            KPYM_HUMAN     PKM2     5315    57769/7.95    15   121   35   51     2D
  **11**                                                           Q12765                              Secernin 1                                          Exocytosis and proteolysis                SCRN1_HUMAN    SCRN1    9805    46353/4.66    12   60    33   61     2D
  **12**                                                           P02768                       Serum albumin precursor                              Starvation response and anti-apoptotic          ALBU_HUMAN      GLB      213    69321/5.92    9    145   12   61     2D
  **13**                                                           P30049                       ATP synthase delta chain                                         ATP Catabolism                      ATPD_HUMAN     ATP5D     513    17479/5.38    3    85    17   25     2D
  **14**                                                           P43686                  26S protease regulatory subunit 6B                               Protein catabolic process                PRS6B_HUMAN    PSMC4    5704    47337/5.09    11   81    26   25     2D
  **15**                                                           P35998                  26S protease regulatory subunit 7                                Protein catabolic process                PRS7_HUMAN     PSMC2    5701    48472/5.72    23   367   52   34     2D
  **16**                                                           Q92878                  DNA repair protein RAD50 (hRAD50)                                      DNA Unwinding                      RAD50_HUMAN    RAD50    10111   153797/6.48   22   31    16   73   2D: IB
  **17**                                                           P49411                 Elongation factor Tu, (EF-Tu) (P43)                               Translational elongation                 EFTU_HUMAN     TUFM     7284    49510/7.26    15   238   34   47     2D
  **18**                                                           Q02790                   FK506-binding protein 4 (PPIase)                                     Protein folding                     FKBP4_HUMAN    FKBP4    2288    51641/5.35    9    99    23   46     2D
  **19**                                                           P10809                                Hsp60                                                Protein stablization                   CH60_HUMAN     HSPD1    3329    61016/5.70    24   708   45   28     2D
  **20**                                                           P32119                           Peroxiredoxin 2                            Anti-apoptosis and maintenance of redox homeostasis   PRDX2_HUMAN    PRDX2    7001    21878/5.66    11   390   40   23     2D
  **21**                                                           P13489                Placental ribonuclease inhibitor (RAI)                     mRNA catabolism & angiogenesis regulation        RINI_HUMAN     RNH1     6050    49810/5.71    17   730   75   29     2D
  **22**                                                           P31943              Heterogeneous nuclear ribonucleoprotein H                         mRNA processing and regulation              HNRH1_HUMAN   HNRNPH1   3187    49067/5.89    14   92    38   18     2D
  **23**                                                           P06576           ATP synthase beta chain, mitochondrial precursor                      Angiogenesis & ATP synthesis               ATPB_HUMAN     ATP5B     506    56525/5.26    15   81    37   27     2D
  **24**                                                           P45973                     Chromobox protein homolog 5                              Chromatin assembly and disassembly            CBX5_HUMAN     CBX5     23468   22211/5.71    10   144   60   24     2D
  **25**                                                           P51571        Translocon-associated protein, delta subunit precursor                  Intracellular protein transport             SSRD_HUMAN     SSR4     6748    18987/5.76    5    236   36   16     2D
  **26**                                                           P00441                    Superoxide dismutase \[Cu-Zn\]                            Apoptosis and cellular maintenance            SODC_HUMAN     SOD1     6647    15795/5.70    3    62    29   11     2D
  **27**                                                           P61326                      Mago nashi protein homolog                                        mRNA processing                      MGN_HUMAN     MAGOH    4116    17153/5.74    9    280   54   17     2D
  **28**                                                           O94832                              Myosin Id                                                Cellular dynamics                    MYO1D_HUMAN    MYOD1    4642    116129/9.44   19   46    15   52     2D
  **29**                                                           P62306                  Small nuclear ribonucleoprotein F                               Spliceosomal snRNP assembly               RUXF_HUMAN     SNRPF    6636     9719/4.70    5    226   33   31     2D
  **30**                                                           P49720                    Proteasome subunit beta type 3                                    Protein catabolism                    PSB3_HUMAN     PSMB3    5691    22933/6.14    8    96    49   55     2D
  **31**                                                           P61769                    Beta-2-microglobulin precursor                          Antigen processing and immune response          B2MG_HUMAN      B2M      567    13706/6.06    2    44    13   16     2D
  **32**                                                           Q13011   Delta3,5-delta2,4-dienoyl-CoA isomerase, mitochondrial precursor                Fatty acid beta oxidation                ECH1_HUMAN     ECH1     1891    35971/6.61    6    76    15   25     2D
  **33**                                                           P25786          Proteasome subunit alpha type 1 Macropain subunit                 Protein catabolism and immune response          PSA1_HUMAN     PSMA1    5682    29537/6.15    7    119   29   16     2D
  **34**                                                           P50990                      T-complex protein 1, theta                                        Protein folding                     TCPQ_HUMAN     CCT8     10694     59451.5     7    46    15   52     2D

10.1371/journal.pone.0070398.t002

###### Details of proteins identified through MALDI-TOF (MS/MS) analysis in Group II.

![](pone.0070398.t002){#pone-0070398-t002-2}

  Sub-group I. Proteins differentially up-regulated in A4-P cells.                                                                                                                                                                                                                                                     
  ------------------------------------------------------------------ -------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------- --------- ------- ------------- ---- ----- ---- ---- ---------- --------
  **1**                                                               P84103                   Splicing factor, arginine/serine-rich 3                                           RNA splicing and processing                             SFRS3_HUMAN     SFRS3    6428    19318/11.64   9    153   54   48   2.608228   2D: IB
  **2**                                                               O94925                                 Glutaminase                                                         glutamine catabolic process                              GLS_HUMAN       GLS     2744    73414/7.85    15   540   36   19   2.103207     2D
  **3**                                                               P31937              3-hydroxyisobutyrate dehydrogenase, mitochondrial                                          oxidation reduction                                HIBADH_HUMAN    HIBADH    11112   35306/8.38    8    199   27   33   2.88171      2D
  **4**                                                               P08754                  Guanine nucleotide-binding ptn G(k),alpha                               negative regulation of adenylate cyclase activity                  GNAI3_HUMAN     GNAI3    2773    40375/5.51    14   166   36   30   4.086129     2D
  **5**                                                               P62873      Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1                    Ras protein signal transduction/hormone signaling                  GNB1L_HUMAN     GNB1L    2782     37353/5.6    13   311   44   24   2.789543     2D
  **6**                                                               P31930             Ubiquinol cytochrome C reductase complex core ptn I                              aerobic respiration/proteolysis/transport                     UQCRC1_HUMAN    UQCRC1    7384    52585/5.94    20   592   53   16   3.247917     2D
  **7**                                                               P28331                   NADH ubiquinone oxidoreductase subunit                                     ATP metabolic process/apoptosis/transport                     NDUFS1_HUMAN    NDUFS1    4719    79465/5.89    21   249   42   35   13.41311   2D: IB
  **8**                                                               O43707                               Alpha actinin-4                                  cellular component movement/protein transport/regulation of apoptosius       ACTN4_HUMAN     ACTN4     81     104788/5.27   31   462   37   38   2.19378      2D
  **9**                                                               Q07955                   Splicing factor, arginine/serine-rich 1                                            mRNA splice site selection                             SFRS1_HUMAN     SFRS1    6426    27597/10.37   6    172   43   29   6.715184   2D: IB
  **10**                                                              Q14974                             Importin β subunit                                NLS-bearing substrate import into nucleus/protein import & translocation      IMB1_HUMAN      IMB1     3837    97108/4.68    30   926   50   11   11.88048   2D: IB
  **11**                                                              Q86UE8               Serine/threonine-protein kinase tousled-like 2                           intracellular signaling pathway/chromatin modification               TLK2_HUMAN      TLK2     11011   80606/8.65    17   45    15   73   6.609533     2D
  **12**                                                              P68363                       Tubulin alpha-ubiquitous chain                                     microtubule-based movement/protein polymerization                 TUBA1B_HUMAN    TUBA1B    10376   50120/4.94    11   88    33   28   4.449974     2D
  **13**                                                              P20700                                  Lamin B1                                                   protein binding/structural molecule activity                    LMNB1_HUMAN     LMNB1    4001    66237/5.11    20   220   37   26   2.990194     2D
  **14**                                                              P61978             Heterogeneous nuclear ribonucleoprotein K (hnRNP K)                           RNA splicing/mRNA processing/signal transduction                 HNRNPK_HUMAN    HNRNPK    3190    50944/5.39    18   425   40   37   2.466555     2D
  **15**                                                              P11021                      78 kDa glucose-regulated protein                                  ER-associated protein catabolic process/anti-apoptosis               HSPA5_HUMAN     HSPA5    3309    72288/5.07    14   753   52   18    26.707      2D
  **16**                                                              O75116                       Rho-associated protein kinase 2                                      cytokinesis/protein amino acid phosphorylation                   ROCK2_HUMAN     ROCK2    9475    160812/5.75   31   73    18   50   7.122232     2D
  **17**                                                              P22314                Ubiquitin-activating enzyme E1 (A1S9 protein)                                  cell death/protein modification process                       UBA1_HUMAN      UBA1     7317    117774/5.49   24   339   25   20   2.52764      2D
  **18**                                                              P05388                   60S acidic ribosomal protein P0 (L10E)                                    ribosome biogenesis/translational elongation                    RPLP0_HUMAN     RPLP0    6175    34252/5.71    12   287   43   23   2.007637     2D
  **19**                                                              P62140   Serine/threonine protein phosphatase PP1-beta catalytic subunit (PP-1B)               cell cycle/cell division/glycogen metabolic process                 PPP1C_HUMAN    PPP1CB    5500    37163/5.84    7    91    19   45   16.02527     2D
  **20**                                                              Q99497                         DJ-1 protein (Oncogene DJ1)                                 cell death/regulation of androgen receptor signaling pathway            PARK7_HUMAN     PARK7    11315   19878/6.33    8    221   53   18   2.102286     2D
  **21**                                                              P50395         Rab GDP dissociation inhibitor beta (Rab GDI beta) (GDI-2)              protein transport/regulation of GTPase activity/signal transduction         GDI2_HUMAN      GDI2     2665    50631/6.11    18   324   44   31   2.027135     2D
  **22**                                                              P24534                    Elongation factor 1-beta (EF-1-beta)                                               translational elongation                             EEF1B2_HUMAN    EEF1B2    1933    24617/4.50    9    329   52   6    2.678404     2D
  **23**                                                              P67936                  Tropomyosin alpha 4 chain (Tropomyosin 4)                                 cellular component movement/muscle contraction                   TPM4_HUMAN      TPM4     7171    28373/4.67    17   507   51   23   2.033974     2D
  **24**                                                              Q9Y297                         F-box/WD-repeat protein 1A                          Wnt receptor signaling pathway/ubiquitin-dependent protein catabolic process    BTRC_HUMAN      BTRC     8945    68822/8.30    17   46    26   50   2.223773     2D
  **25**                                                              Q92973                       Transportin 1 (Importin beta-)2                          interspecies interaction between organisms/protein import into nucleus       TNPO1_HUMAN     TNPO1    3842    101244/4.81   15   209   17   12   4.892821     2D
  **26**                                                              P06733              Alpha enolase 2-phospho-D-glycerate hydro-lyase)                              glycolysis/negative regulation of cell growth                    ENO1_HUMAN      ENO1     2023    47008/6.99    15   330   42   73   2.858116     2D
  **27**                                                              P13645                               Cytokeratin 10                                                           epidermis development                                KRT10_HUMAN     KRT10    3858    59483/5.13    18   281   32   15   141.9166   2D: IB
  **28**                                                              Q03252                                  Lamin B2                                                           Structural molecule activity                            LMNB2_HUMAN     LMNB2    84823   67647/5.29    30   603   51   22   7.605702     2D
  **29**                                                              Q9NR28            Diablo homolog, Mitochonria-deriver caspase cativator                  Activation of caspase activity by Cyt C/ Induction of appoptosis         DIABLO_HUMAN    DIABLO    56616   27114/5.68    11   140   39   28   4.085068   2D: IB
  **30**                                                              P08670                                  Vimentin                                                           cellular component movement                              VIM_HUMAN       VIM     7431    53488/5.06    32   939   42   73   3.239119   2D: IB
  **31**                                                              P50224                 Monoamine-sulfating phenol sulfotransferase                          catecholamine metabolic process, steroid metabolic process            SULT1A3_HUMAN   SULT1A3   4E+05   34174/5.68    12   124   49   31   6.744596     2D

  Sub-group II. Proteins differentially upregulated in A4-T cells.                                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------ -------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ---------------- ---------- ------- -------------- ---- ------ ---- ---- ---------- --------
  **1**                                                               P23526                         Adenosylhomocysteinase                                                          one-carbon metabolic process                                      AHCY_HUMAN       AHCY      191     47554/5.92    16   223    33   29   2.828966     2D
  **2**                                                               P05787                             Cytokeratin 8                                                                cytoskeleton organization                                        KRT8_HUMAN       KRT8     3856     53510/5.52    33   530    53   16   2.141424   2D: IB
  **3**                                                               P63261                              Gamma actin                                                                cellular component movement                                      ACTG1_HUMAN      ACTG1      71      41766/5.31    15   417    49   30   4.030835   2D: IB
  **4**                                                               Q15084                     Protein disulfide isomerase A6                                                 cell redox homeostasis/protein folding                                PDIA6_HUMAN      PDIA6     10130    48091/4.95    12   357    35   8    8.528689     2D
  **5**                                                               P07900                              HSP 90 Alpha                                                   cellular chaperone-mediated protein complex assembly                        HSP90AA1_HUMAN   HSP90AA1   3320     84490/4.94    12    60    18   50   2.561739     2D
  **6**                                                               P52788                           Spermine synthase                                              methionine metabolic process/spermine biosynthetic process                       SMS_HUMAN        SMS      6611     41242/4.87    9     68    23   26   2.087467     2D
  **7**                                                               O00410                           Importin subunit-3                                                     NLS-bearing substrate import into nucleus                                IPO5_HUMAN       IPO5     3843    123550/4.83    21   251    23   19   2.005113     2D
  **8**                                                               P14625                     Endoplasmin precursor (GRP94)                                          ER-associated protein catabolic process/anti-apoptosis                         ENPL_HUMAN       ENPL     7184     92411/4.76    36   609    47   7    56.43346     2D
  **9**                                                               Q14764                       Major vault protein (MVP)                                                          mRNA and protein transport                                       MVP_HUMAN        MVP      9961     99135/5.34    23   214    28   20   7.717112     2D
  **10**                                                              P08238                     Heat shock protein HSP 90-beta                                                            protein folding                                           HSP90AB1_HUMAN   HSP90AB1   3326     83081/4.97    16    64    17   40   5.908433     2D
  **11**                                                              Q99426                      Tubulin-specific chaperone B                                             cell differentiation/nervous system development                             TBCB_HUMAN       TBCB     1155     27308/5.06    9     79    33   45   3.162533     2D
  **12**                                                              Q9BT78                   COP9 signalosome complex subunit 4                                                          protein binding                                            COPS4_HUMAN      COPS4     51138    46240/5.57    15   207    37   17   2.618724     2D
  **13**                                                              O15372                     eIF-3 gamma (eIF3 p40 subunit)                                                 regulation of translational initiation                                EIF3H_HUMAN      EIF3H     8667     39905/6.09    13    71    28   37   3.177448     2D
  **14**                                                              P29692                 Elongation factor 1-delta (EF-1-delta)                       positive regulation of I-kappaB kinase/NF-kappaB cascade/translational elongation           EEF1D_HUMAN      EEF1D     1936     30972/4.90    11   204    43   5    4.075992     2D
  **15**                                                              Q15366                 Poly(rC)-binding protein 2 (Alpha-CP2)                                              RNA splicing/mRNA metabolic process                                  PCBP2_HUMAN      PCBP2     5094     38556/6.33    10    72    35   41   4.952897     2D
  **16**                                                              P28070                Proteasome subunit beta type 4 precursor                anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process    PSMB4_HUMAN      PSMB4     5692     29173/5.72    7     96    27   28   3.783769     2D
  **17**                                                              P27348              14-3-3 protein tau (14--3--3 protein theta)                                    negative regulation of transcription, DNA-dependent                          YWHAQ_HUMAN      YWHAQ     10971    27747/4.68    15   216    55   18   2.880806     2D
  **18**                                                              Q13952                  Nuclear factor NF-Y protein chain C                                            protein folding/regulation of transcription                               NFYC_HUMAN       NFYC     4802     50271/5.78    3     66    7    15   4.573116     2D
  **19**                                                              P60228      Eukaryotic tanslation initiation factor 3 subunit eIF-3 p48                    translational initiation/nuclear-transcribed mRNA catabolic process                  EIF36_HUMAN      EIF36     3646     52187/5.71    11    49    24   36   8.501138     2D
  **20**                                                              P13693            Translationally controlled tumor ptn(TCTP)(p23)                                    anti-apoptosis/cellular calcium ion homeostasis                             TPT1_HUMAN       TPT1     7178     19583/4.84    7     70    33   20   3.649924     2D
  **21**                                                              P08779                             Cytokeratin 16                                                      cell proliferation/cytoskeleton organization                             KRT16_HUMAN      KRT16     3868     51105/4.98    11   101    24   26   2.869215     2D
  **22**                                                              P04792                     HspB1Heat shock 27 kDa protein                           anti-apoptosis/cellular component movement/regulation of translational initiation           HSPB1_HUMAN      HSPB1     3315     22768/5.98    10   163    46   11   3.099848     2D
  **23**                                                              P60842              Eukaryotic initiation factor 4A-I (eIF4A-I)                                                        translation                                              EIF4A1_HUMAN     EIF4A1    1973     46125/5.32    21   574    45   40   6.608386     2D
  **24**                                                              P17987                T-complex protein 1, alpha (TCP-1-alpha)                                           protein folding/tubulin complex assembly                                TCP1_HUMAN       TCP1     6950     60306/5.80    20   144    38   22   3.35298      2D
  **25**                                                              P62258                        14--3--3 protein epsilon                                          apoptosis/induction of apoptosis by extracellular signals                       YWHAE_HUMAN      YWHAE     7531     29155/4.63    16   257    61   30   2.060479     2D
  **26**                                                              P12004           Proliferating cell nuclear antigen (PCNA) (Cyclin)                                 DNA replication/cell proliferation/mismatch repair                           PCNA_HUMAN       PCNA     5111     28750/4.57    11   519    52   21   3.664895     2D
  **27**                                                              Q01105                              SET protein                                                        DNA replication/nucleocytoplasmic transport                               SET_HUMAN        SET      6418     33469/4.23    10   491    38   25   3.358717     2D
  **28**                                                              P27797                      Calreticulin precursor ERp60                                     cell cycle arrest/protein stabilization/regulation of apoptosis                     CALR_HUMAN       CALR      811     48112/4.29    14   1180   49   35   11.82921     2D
  **29**                                                              P28072   Proteasome subunit beta type 6 precursor (Proteasome delta chain)    anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process    PSMB6_HUMAN      PSMB6     5694     25341/4.80    7    166    30   15   2.770366     2D
  **30**                                                              P08727                             Cytokeratin 19                                                  response to estrogen stimulus/sarcomere organization                         KRT19_HUMAN      KRT19     3880     44079/5.04    30   861    69   20   2.032384   2D: IB
  **31**                                                              O94905                             Protein C8orf2                                                        ER-associated protein catabolic process                                ERLIN2_HUMAN     ERLIN2    11160    37815/5.47    9    124    27   40   4.069573     2D
  **32**                                                              P14923                 Junction plakoglobin (Desmoplakin III)                         cell migration/endothelial cell-cell adhesion/detection of mechanical stimulus             JUP_HUMAN        JUP      3728     81447/5.95    19   230    30   45   2.078487     2D
  **33**                                                              P23381        Tryptophanyl-tRNA synthetase (Tryptophan\--tRNA ligase)                          regulation of angiogenesis/tryptophanyl-tRNA aminoacylation                       WARS_HUMAN       WARS     7453     53132/5.83    10    87    20   47   2.423008     2D
  **34**                                                              P15311                              Ezrin (p81)                                                actin filament bundle assembly/membrane to membrane docking                       EZR_HUMAN        EZR      7430     69225/5.95    12   510    54   32   3.924348   2D: IB
  **35**                                                              Q9Y230   RuvB-like 2 (48-kDa TATA box-binding protein-interacting protein)                    DNA recombination & recombination/regulation of transcription                     RUVBL2_HUMAN     RUVBL2    10856    51125/5.49    22   292    47   42   4.228731     2D
  **36**                                                              P51570                    Galactokinase (Galactose kinase)                                       carbohydrate phosphorylation/galactose metabolic process                       GALK1_HUMAN      GALK1     2584     42246/6.04    14   129    34   37   2.024403     2D
  **37**                                                              P04181          Ornithine aminotransferase, mitochondrial precursor                                                 visual perception                                            OAT_HUMAN        OAT      4942     48504/6.57    16   223    41   29   3.552906     2D
  **38**                                                              Q10713      Mitochondrial processing peptidase alpha subunit, precursor                                                proteolysis                                              PMPCA_HUMAN      PMPCA     23203    58216/6.45    14   106    27   82   33.28102     2D
  **39**                                                              Q9Y265   RuvB-like 1 (49-kDa TATA box-binding protein-interacting protein)                         DNA recombination/cell division/regulation of growth                         RUVBL1_HUMAN     RUVBL1    8607     50196/6.02    15   135    30   76   11.4513      2D
  **40**                                                              P04083                               Annexin A1                                 anti-apoptosis/cellular component movement/cell surface receptor linked signaling pathway       ANXA1_HUMAN      ANXA1      301     38559/6.64    16   487    57   65   12.0573    2D: IB
  **41**                                                              P07237              Protein disulfide-isomerase precursor (PDI)                                                  cell redox homeostasis,                                         P4HB_HUMAN       P4HB     5034     57081/4.76    17   399    30   40   2.336195     2D
  **42**                                                              P07910   Heterogeneous nuclear ribonucleoproteins C1/C2 (hnRNP C1/hnRNP C2)                               nuclear mRNA splicing, via spliceosome                                HNRNPC_HUMAN     HNRNPC    3183     33667/4.95    12   246    35   47   2.011891     2D
  **43**                                                              P17655                     Calpain-2 subunit II precursor                                                              proteolysis                                              CAPN2_HUMAN      CAPN2      824     79828/4.88    13   121    24   15   19.41388     2D
  **44**                                                              P08107                      Heat shock 70 kDa protein 1                                                              Stress response                                            HSPA1A_HUMAN     HSPA1A    3303     70009/5.48    26   676    40   22   2.015034   2D: IB
  **45**                                                              P38646     Stress-70 protein (75 kDa glucose regulated protein) (GRP 75)                                protein import into nucleus, translocation                              GRP75_HUMAN      GRP75     3842     73635/5.87    23   250    34   27   2.112865   2D: IB
  **46**                                                              P30048   Thioredoxin-dependent peroxide reductase, mitochondrial precursor                cell redox homeostasis/regulation of mitochondrial membrane potential                 PRDX3_HUMAN      PRDX3     10935    27675/7.67    7    210    37   17   2.91228      2D
  **47**                                                              Q9BS26                Thioredoxin domain-containing protein 4                                                     cell redox homeostasis                                        TXND4_HUMAN      ERP44     23071   46941.4/5.09   15   441    39   38   4.879818     2D
  **48**                                                              P05783                             Cytokeratin 18                                                     protein binding, structural molecule activity                             KRT18_HUMAN      KRT18     3875     53488/5.34    16   627    43   27   4.928731   2D: IB

Categorization of functional pathways based on reported ontologies and expression validation {#s2c}
--------------------------------------------------------------------------------------------

Gene ontology analyses further identified distinct molecular functionalities and pathways associated with the identified protein profiles in the two cell types ([Fig. 1D](#pone-0070398-g001){ref-type="fig"}.i). Thus, several cellular regulatory mechanisms including protein biosynthesis, cytoskeleton organization, signal transduction, regulation of apoptosis and protein degradation were largely enriched in and contributed to the functionality of A4-P cells. These were suggested to have a cross-talk with other pathways such as protein and energy metabolism, RNA metabolism, cellular differentiation and redox reactions.

Conversely, functional grouping of the proteins in A4-T cells comprised pathways associated with the classical hallmarks of cancer cells *viz*. resistance to apoptosis, energy metabolism, cell proliferation, angiogenesis and invasion and metastases ([Fig. 1D](#pone-0070398-g001){ref-type="fig"}.ii). Thus, molecules involved in associated with protein biosynthesis, folding and transport control the dynamic process of protein metabolism in transformed cells towards matching its proliferative activities.

Towards confirming levels of some of the identified proteins, their expressions were validated between A4-P and A4-T cells through immunoblotting ([Fig. 1E](#pone-0070398-g001){ref-type="fig"}; [Fig. 2A,B,C,D](#pone-0070398-g002){ref-type="fig"}). SeOvCa is unique in that, transformation is associated with expression of epithelial markers [@pone.0070398-Auersperg1]. Enhanced vimentin expression in A4-P cells suggest mesenchymal while elevated levels of Cytokeratin 8 and 18 in A4-T cells correlate with epithelial features respectively ([Fig. 1E](#pone-0070398-g001){ref-type="fig"}), besides being in concordance with their cell morphology and the prevalent hypothesis.

![Validation of differentially expressed proteins and induction of RXR-γ levels on retinoid treatments.\
Quantitative validation of the expression and fold change of some proteins, identified in both groups; Group I proteins, A, exclusively expressed in A4-P and B, in A4-T cell respectively; whereas D, group-II proteins quantitatively up-regulated in A4-P cells and E, in A4-T. E. Relative expression of RXR-γ and β-actin in CRA, ADA or TTNPB retinoids treated A4-P (P) and A4-T (T) cells validated through immunoblotting. F. Quantitation of relative RXR-γ expression in A4-P and A4-T cells. Statistical analysis showing test of significance (\*-control A4-P and retinoids treated cells; \$- control A4-P and retinoids treated cells).The data shown are representative of three separate experiments and depicted as mean ± SEM \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.](pone.0070398.g002){#pone-0070398-g002}

Functional characterization of RXR-γ an exclusive Group I protein {#s2d}
-----------------------------------------------------------------

Ten Group I proteins were expressed exclusively in the A4-P cells (EEx proteins). Literature-based functional annotation led to their categorizat ion into four functional groups *viz.*

i.  *Cell differentiation and apoptosis --* RXR-γ, PRDX4;

ii. *Cell proliferation* -- GNA11, PIBF-1, ANXA5, Cathepsin D (CTSD);

iii. *Mitosis and cytokinesis* -- KLH9;

iv. *Epithelial-mesenchymal transition (EMT)* -- TPM1, ANXA5.

While all the above functions are relevant in the process of transformation, we focused on studying the functionality of cellular differentiation and apoptosis that is critical in maintaining tissue homeostasis and known to be regulated by RXR-γ at the transcriptional level by dimerizing with retinoic acid or retinoic acid X receptors (RAR or RXR respectively) or other permissive heterodimer partners like PPAR-γ [@pone.0070398-Mangelsdorf1], [@pone.0070398-Konopleva1], [@pone.0070398-deLera1]. We thus decided to investigate the role of RXR-γ in our epithelial ovarian cancer progression model.

RXR-γ interactions with nuclear receptors and modulation of cellular differentiation in A4-P cells upon retinoids treatment {#s2e}
---------------------------------------------------------------------------------------------------------------------------

Retinoid treatment enhanced RXR-γ levels in A4-P cells; and interestingly, resumed significant expression in A4-T cells as well ([Fig. 2E,F](#pone-0070398-g002){ref-type="fig"}). CRA and ADA individual treatment elevated RXR-γ levels in both cell types, though this induction was less effective in combination with TTNPB. Towards validation of RXR-γ interactions with other nuclear receptors, co-immunoprecipitation and immunoblotting affirmed interactions with PPAR-γ, RAR-γ, RXR-α and RAR-α in pre-transformed cells ([Fig. 3A,B](#pone-0070398-g003){ref-type="fig"}). Evaluation of RXR-γ involvement in cellular differentiation was achieved through profiling epithelial markers E-cadherin (E-cad), Cytokeratin 18 (CK-18) and Mucin-1 (Muc-1) at gene expression and protein levels, in steady state and on exposure to natural *viz*. CRA and synthetic retinoids (ADA and TTNPB) ([Fig. 3C](#pone-0070398-g003){ref-type="fig"}). At steady state, lower expression of E-Cad was observed in A4-P cells. Expression of E-Cad further increased with CRA and also with ADA; CRA was given alone or in combination with ADA and TTNPB. Levels of E-Cad, CK18 and Muc-1 were endogenously higher in A4-T cells. Synthetic retinoid ADA alone or in combination with CRA upregulated CK18 expression in both cell types. Although, specific role of TTNPB in cellular differentiation is unknown, TTNPB treatment resulted in minor upregulation of differentiation markers. All three markers were enhanced in response to retinoid exposure in A4-P cells thereby affirming the involvement of RXR-γ in modulation of cellular differentiation. Retinoid treatment in the A4-T cells resulted in induction of RXR-γ without any significant alterations in the levels of these epithelial differentiation marker at gene expression and protein levels ([Figs. 3D,3E](#pone-0070398-g003){ref-type="fig"}).

![RXR-γ interacts with a number of nuclear receptors and modulates cellular differentiation.\
A. Co-Immunoprecipitation (Co-IP) with RXR-γ showing eluted Immunocomplex by silver staining. B. Validation of RXR-γ indicating interaction in Co-IP with RXR-γ with PPAR-γ, RAR-γ, RXR-α and RAR-α in A4-P cells validated through immunoblotting. C. Expression profiling of CK-18, Muc-1 and E-Cadherin at transcriptional (Tr) and protein (Pr) performed by semi-quantitative RT-PCR and immunoblotting in CRA, ADA or TTNPB retinoids treated A4-P (P) and A4-T (T) cells. D. Quantitation of mRNA expression of E-Cad, CK18 and MUC1 epithelial differentiation markers in A4-P (P; line) and A4-T cells (T; dashed line) upon retinoids treatment validated through RT-PCR. E. Quantitation of protein expression of E-Cad, CK18 and MUC1 makers in A4-P (P; line) and A4-T cells (T; dashed line) upon retinoids treatment validated through immunoblotting. Data shown are representative of three separate experiments depicted as mean ± SEM \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.](pone.0070398.g003){#pone-0070398-g003}

Retinoid induced RXR-γ levels sensitize transformed cells towards apoptosis via intrinsic pathway {#s2f}
-------------------------------------------------------------------------------------------------

Role of RXR-γ in mediating apoptosis in response to natural and synthetic retinoids was evaluated ([Fig. 4A](#pone-0070398-g004){ref-type="fig"}). At steady state, apoptosis was significantly lower in A4-T cells as compared to A4-P cells indicating acquisition of resistance to apoptosis during the transformation process. Apoptosis was enhanced in both cell types on exposure to CRA and ADA -- either alone or in combination ([Fig.4B](#pone-0070398-g004){ref-type="fig"}). While TTNPB by itself failed to induce cell death, in combination with ADA and CRA it sensitized A4-T cells to apoptosis. Retinoid mediated activation of RXR-γ expression was also found to correlate directly with higher levels of apoptosis ([Fig. 2E,F](#pone-0070398-g002){ref-type="fig"}). We profiled expression of the transcription factor Snail (that antagonizes p53-mediated pro-survival signaling through active repression of the pro-apoptotic molecules PUMA/BBC3, ATM and PTEN in ovarian cancer cells under stress; [@pone.0070398-Kurrey1]) to evaluate the effect of RXR-γ led apoptosis on it. Caspase 9, a marker of intrinsic apoptosis pathway, upregulated during RXR-γ and PPAR-γ induction and Bcl-2 as markers of apoptosis [@pone.0070398-Fulda1]. Snail and Bcl-2 expression were reduced, while significantly elevated expression of RXR-γ, PPAR-γ and Caspase 9 were evident on retinoid treatment ([Fig. 4C, 4D, 4E](#pone-0070398-g004){ref-type="fig"}). The expression of these molecules was further enhanced on combinatorial retinoid treatment. We further probed the effects of retinoids on cell cycle profiles ([Fig. S1A,1B](#pone.0070398.s001){ref-type="supplementary-material"}). As expected, steady state A4-T cells possess higher S & G2/M populations than A4-P cells indicating active proliferation. CRA treatment enhances apoptosis along with G2/M arrest in A4-P cells while ADA and TTNPB induce only G2/M arrest. In the combinatorial treatments, CRA with ADA or presence of all three retinoids induced a G1/S arrest in transformed cells.

![RXR-γ levels sensitize cellular apoptosis in A4-T cells upon retinoid treatment.\
A. Annexin V-FITC assay data showing apoptosis in A4-P and A4-T cells on different retinoids treatment regimes; where i. having no retinoid treatment, ii. treated with CRA, iii. with ADA and iv. with both having alternative treatment of another synthetic retinoid i.e. TTNPB. B. Statistical analysis of apoptosis assay showing significant apoptosis among both cell types in different sets of retinoid treatment. C. Expression analyses of RXR-γ, PPAR-γ, Bcl-2, Caspase 9 and snail at transcriptional (Tr.) and protein level (Pr.) through RT-PCR and immunoblotting respectively. D. Quantitation of mRNA expression, i. expression of RXR-γ, PPAR-γ, Caspase 9, Bcl-2 and snail upon retinoids treatment in A4-P cells whereas, ii. shows their levels in A4-T cells on validation through RT-PCR. E. Quantitation of protein expression, i. expressions of RXR-γ, PPAR-γ, Caspase 9, Bcl-2 and snail in A4-P cells whereas, ii. shows their levels in A4-T cells upon retinoids treatment validated through immunoblotting.](pone.0070398.g004){#pone-0070398-g004}

In vivo retinoid treatment significantly reduce xenograft growth in NOD-SCID mice through RXR-γ mediated sensitization of transformed cells towards apoptosis {#s2g}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

We further extended the above re-sensitization of RXR-γ levels in A4-T cells effects obtained *in vitro* to experimental tumors ([Fig. 5A](#pone-0070398-g005){ref-type="fig"}). Mean tumor volume ([Figs. 5B,5C](#pone-0070398-g005){ref-type="fig"}) at each treatment point along with mean tumor volume and weight at 7th week ([Figs. S1C, S1D](#pone.0070398.s001){ref-type="supplementary-material"}) showed significant reduction in retinoid treated mice tumors vs. those in DMSO treated controls. Overall, the combinatorial retinoid treatment was most effective. The distinctly upregulated RXR-γ expressions in the retinoid-treated tumors strongly suggest sensitization of transformed A4 cells to apoptosis. Combined effect of retinoids was found to be most lethal for tumor growth through resumed RXR-γ mediated apoptosis of tumor cells *in vivo*. RXR-γ levels were found significantly higher in all 5 sets including CRA, CRA & TTNPB, ADA, ADA & TTNPB and CRA, ADA & TTNPB; in comparison to DMSO vehicle control. This is a definitive correlation with RXR-γ stimulation and induction of apoptosis in these cells *in vitro* ([Fig.5D](#pone-0070398-g005){ref-type="fig"}).

![*In vivo* retinoid treatment resumes RXR-γ levels and reduces xenograft growth.\
A. Experimental procedure illustrating retinoids treatment regime in NOD-SCID mice. Mice were observed upto 3 week until tumor size grows 25--30 mm^3^, treatment of DMSO, CRA, CRA+TTNPB, ADA, ADA+TTNBP and CRA+ADA+TTNBP started on 4^th^ week and proceeded upto 7^th^ week. B. Graphical representation showing tumor volumes of control and retinoids treated NOD-SCID mice at different time points. C. Comparative tumor sizes of control and retinoids treated tumors. D. Quantitative expression of RXR-γ in control and retinoids treated tumors validated through immunoblotting. Data shown are representative of three separate experiments (n = 6 for *in vivo* experiments) and depicted as mean ± SEM \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.](pone.0070398.g005){#pone-0070398-g005}

Discussion {#s3}
==========

The existence of several histological sub-types that correlate with different cell(s)-of-origin in ovarian cancer [@pone.0070398-Auersperg2] remains a hurdle in the establishment of representative progression models in this disease. This is in contrast to other malignancies such as prostate cancer in which such models have been applied over the last two decades in elucidating molecular mechanisms of disease [@pone.0070398-Xie1], [@pone.0070398-Simoneau1], [@pone.0070398-Califano1], [@pone.0070398-Garnis1]. In the present study, detailed exclusive and differential protein profiling of a progression model established earlier in our lab provided novel insights into altered molecular patterns during SeOvCa progression. A4-P cells with replicative immortality represent a pre-neoplastic stage while A4-T cells with aggressive and metastatic characteristics are representative of transformation and disease progression.

Our data affirms that the two functional states of the model are associated with distinct protein profiles. Within the group of proteins exclusive to the A4-P cells, characterization of the role of RXR-γ revealed a sensitivity of the pre-transformed cells to apoptosis and differentiation as described earlier [@pone.0070398-Gudas1]. Compromised RXR-γ levels are also reported in several malignancies including non-small cell lung cancer [@pone.0070398-Brabender1]; where it also has been reported that epigenetic silencing of RXR-γ correlated with decreased overall survival of patients [@pone.0070398-Lee1]. In our pre-transformed cells, RXR-γ cooperates with PPAR-γ, RAR-γ, RAR-α and RXR-α to form functional heterodimeric complexes, where RXR-γ with PPAR-γ coordinates cellular apoptosis through the intrinsic pathway confirmed with elevated Caspase-9 levels. Further, we observed that RXRγ activation in transformed cells re-sensitizes them to apoptosis as a synergistic effect of agonists that mediate cytotoxic effects *in vitro* as well as in experimental tumors ([Fig. 6](#pone-0070398-g006){ref-type="fig"}). This is an important identification towards application of retinoid-based therapies. In this study, we characterized the pleotropic nature of RXR-γ signaling in our SeOvCa-progression model system. Loss of RXR-γ levels indicated to facilitate mechanistic benefits to transformed cells towards acquisition of resistance to apoptosis; consequently, retinoid-sensitized tumor cells upregulate RXR-γ levels leading to significant cell death.

![Schematic model showing modulation of cellular differentiation and apoptosis by RXR-γ during the progression of epithelial ovarian cancer.\
A. RXR-γ modulation at steady state in pre-transformed cells; retinoids treatment enhances RXR-γ levels and scale up apoptosis (upon RXR-γ interaction with PPAR-γ) and expression of epithelial differentiation specific markers (upon RXR-γ interactions with RAR-γ, RXR-α and RAR-α). B. Deficiency of RXR-γ providing benefits of resistance to apoptosis to transformed cells; retinoid treatment induced RXR-γ levels sensitize these cells towards significant apoptosis.](pone.0070398.g006){#pone-0070398-g006}

The present proteomics approach is a first account of changes in SeOvCa that reflect on various transformation--associated functional pathways. Significantly, RXR-γ signaling could be a potential gateway in preventing disease progression. The elucidation of RXR-γ signaling extends contemporary approaches of cellular transformation in SeOvCa that can now be exploited further in development and evaluation of new therapeutic modalities.

Material and Methods {#s4}
====================

Ethics statement {#s4a}
----------------

All animal work was conducted with the National Centre for Cell Science (NCCS) Institutional Animal Ethics Committee (IAEC) approval of experiments in the NCCS Experimental Animal House (EAH) Facility, and was performed as per the norms, laws and policies laid down by the committee.

Cell culture, treatments and transfections {#s4b}
------------------------------------------

Derivation of the A4 progression model of pre-transformed and transformed SeOvCa cells (A4-P and A4-T cells) is described earlier [@pone.0070398-Bapat1], [@pone.0070398-Wani1]. Retinoid (RXR-γ ligand) treatment was carried out using either natural retinoid *viz*. 9 *Cis* Retinoic acid (CRA;10 µM) or synthetic retinoids Adapalene (ADA; 2 µM; RAR agonist) or 4-\[(E)-2-(5,6,7,8 --Tetrahydro - 5,5,8,8 --tetramethyl -- 2 naphthalenyl) -- 1 -propenyl\] benzoic acid Arotinoid acid (TTBPB; 10µM; RXR and RAR agonist) for 48h.

Sample preparation, 2-Dimensional gel electrophoresis (2DE) and image analyses {#s4c}
------------------------------------------------------------------------------

Cell pellets (10^7^) of A4-P and A4-T were suspended in 500 µl ml of urea lysis buffer containing 8 M Urea, 2 M Thiourea,100 mM DTT, 2% CHAPS and 0.2% ampholytes with protease-inhibitor cocktail (Amersham USB Guideline). Cell extract was allowed to be mixed for at least 15 minutes and incubated for 30 minutes at room temperature to facilitate proper protein solublisation. Protein samples were further centrifuged (110,000g for 1 hour at 4°C) and suspension was collected. Protein concentration was estimated with 2DE quant kit (GE healthcare) at 480 nm (Bekman Coulter). Prepared samples were run on first dimension (pI) followed by of second dimension in denaturing SDS-PAGE (Mw). A total of 350 µg whole cell protein lysate was taken on 18 cm immobilized pH gradient (IPG) strip (pH 4--7) and rehydrated overnight. A three step IEF voltage program was prepared to the strips on a Protean IEF cell (Bio-Rad): 50 V for 20 mins, 10,000 V for 2 hours minutes and 10,000 V for 45,000 V-hr. Strips were further reduced by incubation in the equilibration/reduction buffer (6 M Urea, 0.375 M Tris pH 8.8, 2% SDS, 20% glycerol, 2% (w/v) DTT (Sigma)) and then alkylated the same buffer but containing 2.5% (w/v) Iodoacetamide (Sigma) instead of DTT. The second dimension was accomplished by running the IPG strips on 1.0 mm-thick of 10%-(w/v)- SDS-PAGE. Gels were stained with mass spectrometry compatible modified coomassie blue (Pierce, Thermo-Fisher) and silver stain. Image acquisition of protein gel was accomplished using Quantity One® software of VersaDocTM system (Bio-Rad Laboratories, USA) with equal parametric values. Image analysis and spot detection were performed on PDQuest 2-DE analysis software advanced version 8.0 (Bio-Rad). For quantitative and qualitative spot comparison across both gels, match-sets (Master set) of six replicates of A4-P and A4-T 2DE-gels were prepared and analysed. Software facilitates annotation of each and individual spot, unique identities were provided to every protein spots of replicate gel. An analysis set of proteins have been prepared to identify spots that are significantly different. Analysis set were made based on identified proteins spots unique to A4-P and A4-T and common spots among two replicate groups with a 2.0 fold quantity variation threshold. A total estimate of matched and unmatched spots was prepared to final images and differential proteins were identified in-between two cell types representative gels.

In-gel digestion and protein identification using MALDI-TOF/TOF {#s4d}
---------------------------------------------------------------

Protein spots in 2DE showing differential expression and satisfying the statistical criteria were selected and excised for in-gel digestion and further MS analyses. Spot excision was performed manually with the help of sterile sharp spot cutter. Briefly, the gel slices were destained in 25 mM ammonium bicarbonate, subsequent dehydrated with a 2∶1 mixture of 50 mM ammonium bicarbonate:100% acetonitrile (ACN) for repeated 3 times each 5 minutes. Gel slices were reduced with 10 mM DTT at 60°C for 1 hour. After cooling, gel slices were incubated for 15 min at room temperature with 50 mM iodoacetic acid. After washing and dehydrating the gel slices with 25 mM ammonium bicarbonate and ACN for 10 min, they were vacuum dried and tryptic digestion performed with 50 mM ammonium bicarbonate containing 20 ug/mL modified proteomic grade trypsin (Sigma-Aldrich) according to the manufacturer\'s instructions and kept on ice for 30 min. Additional 25 mM ammonium bicarbonate was added and digestion was continued overnight at 37°C. Extracted peptides were completely dried using a speedvac and re-suspended in 10 µl of 20% Ammonium Bicarbonate and 1% formic acid solution.

After processing through the Zip-Tip pipette tips (Millipore, USA), peptide mixtures were dissolved with matrix solution. The matrix used for MALDI analysis was a-cyano-4-hydroxycinnamic acid (Sigma) at 20 mg/ml in 50% acetonitrile, 0.1% trifluoroacetic acid. Equal volumes of peptide and matrix solution were mixed, and 1 µl of the resulting solution was spotted on a stainless steel MALDI sample plate. Spectra of digested peptides were acquired on a 4800 MALDI-TOF/ TOF mass spectrometer (AB Sciex, Framingham, MA) linked to 4000 series explorer software (version 3.5.3). Produced mass spectra were recorded in a reflector mode within a mass range from 800 to 4000 Da, using a Nd:YAG 355nm laser. The acceleration voltage and extraction voltage were set on 20 kV and 18 kV respectively. Six point calibration of the instrument was performed with peptide standard kit (AB Sciex). All of the MS spectra were obtained from accumulation of 900 shots. MS/MS spectra were acquired with a total accumulation of 1500 laser shots and collision energy of 1Kv. At completion of MS survey scans, the data was processed to generate a list of precursor ions for interrogation by MS/MS. The combined MS and MS/ MS peak lists were explored using the GPS^TM^ Explorer software version 3.6 (AB Sciex). Protein identification was performed by MS/MS ion search using MASCOT (version 2.1) (<http://www.martixscience.com>) search engine against the SwissProt database. The search parameters were set as follows: all entries and human taxonomy, trypsin digestion and one missed cleavage, fixed modifications: carbamidomethylation of cysteine residues, mass tolerance: 150 ppm for MS and 0.4 Da for MS/MS. Identified proteins having at least two unique matched peptides were selected with an identification confidence interval threshold of ≥95%.

Co-immunoprecipitation and Immunoblotting {#s4e}
-----------------------------------------

1mg cellular protein extracted in RIPA buffer (1M Tris pH 7.4, 4M NaCl, 0.5M EDTA, NP-40, 10% SDS) was incubated with 5 µg RXR-γ antibody for 2 h at 4°C. This was followed with overnight incubation with 20 µl protein-A agarose (Amersham, GE Healthcare). Complex-bound bead were collected through centrifugation at 12,000 g for 1 min, was washed with TBS (50 mM Tris--HCl, 150 mM NaCl, PMSF), resuspended in 2×SDS buffer and heated at 95°C for 5 min. Eluted proteins were resolved on 2--4% denaturing SDS-PAGE at 80 V followed by immunoblotting, that was performed as described earlier [@pone.0070398-Kurrey1]. Details of antibodies used in the study will be made available on request.

Semi-quantitative reverse transcription-PCR {#s4f}
-------------------------------------------

Semi-quantitative reverse transcription-PCR was performed under standard conditions as described earlier [@pone.0070398-Kurrey1] and amplified products resolved on a 1.5% agarose gel; β-actin was used as internal control.

Cell cycle and apoptosis assay {#s4g}
------------------------------

Cell cycle analysis of transfected and retinoid-treated cells was done with PI (Propidium-Iodide) staining using standard protocols [@pone.0070398-Sharma1]. Data acquisition and analysis was performed on FACSCalibur (Becton Dickinson, San Diego, CA, http:// [www.bdbiosciences.com](http://www.bdbiosciences.com)) using ModFit analytical software. Annexin V--FITC apoptosis assay was performed as described earlier [@pone.0070398-Sharma1] using FACSCanto II (Becton Dickinson); DiVa software (Becton Dickinson) was used for data analysis.

*In vivo* studies {#s4h}
-----------------

In vivo experimentation was performed in NOD/ SCID mice bred and maintained at Experimental Animal Facility, NCCS; and carried out as per the norms, laws and policies of the institutional ethical committee. A4-T cells (2.5×10^6^) were injected subcutaneously (SC) in thighs of 4--6 week-old male mice and observed every 48 h till 3 weeks for tumor formation. Injections of retinoids i.e. 9Cis RA, ADA and TTNPB as well in combination started while tumor size reaches 25--30 mm^3^ in volume, where DMSO given to vehicle control mice. Treatments of DMSO, 25 µM 9Cis RA, 25 µM 9Cis RA+10 µM TTNPB, 5 µM ADA, 5 µM ADA +10 µM TTNPB and 25 µM 9Cis RA+5 µM ADA +10 µM TTNPB retinoids injections were given twice per week into the tumor of each mouse. Tumor size was monitored in two perpendicular directions using Vernier\'s calliper; individual tumor weights and sizes were more precisely quantified in the seventh week after sacrificing mice to harvest tumors.

Statistical analysis {#s4i}
--------------------

All experiments were carried out at least in triplicate; data are expressed as mean ± SEM of three independent experiments. The significance of difference in the mean values was determined using two--tailed Student\'s t test; p\<0.05 was considered significant. ANOVA test was performed to compare gene and protein expression and tumor volume over time between treatment groups at a significance level of \<0.05. Student-Bonferroni test was used to evaluate sub-comparisons to control the test-wise error rate.

Supporting Information {#s5}
======================

###### 

**A. PI based FACS analysis of cell cycle in A4-P and A4-T cells on different treatment regime of no retinoid treatment, treatment with CRA, ADA and with both having alternative treatment of another synthetic retinoid i.e. TTNPB, showing percentage of relative populations in different cell cycle phases.** B. Quantitation of different cell cycle phases of A4-P and A4-T cells on different retinoid treatments. C. Graphical representation showing tumor volumes of retinoids treated NOD-SCID mice. D. Graphical representation showing tumor weight of retinoids treated NOD-SCID mice. The data shown are representative of three separate experiments and depicted as mean ± SEM \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.

(DOC)

###### 

Click here for additional data file.

###### 

**Summary of total numbers of proteins identified between A4-P and A4-T cells through 2DE analyses followed by MALDI-TOF-TOF (MS/MS) identification.**

(DOC)

###### 

Click here for additional data file.
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